Effects of haloperidol on selective attention: a combined whole-head MEG and high-resolution EEG study.
We used 122-channel magnetoencephalography (MEG) and 64-channel electroencephalogrphy (EEG) simultaneously to study the effects of dopaminergic transmission on human selective attention in a randomized, double-blind placebo-controlled cross-over design. A single dose of dopamine D2 receptor antagonist haloperidol (2 mg) or placebo was given orally to 12 right-handed healthy volunteers 3 hours before measurement. In a dichotic selective attention task, subjects were presented with two trains of standard (700 Hz to the left ear, 1,100 Hz to the right ear) and deviant (770 and 1,210 Hz, respectively) tones. Subjects were instructed to count the tones presented to one ear; whereas, the tones presented to the other ear were to be ignored. Haloperidol significantly attenuated processing negativity (PN), an event-related potential (ERP) component elicited by selectively attended standard tones at 300-500 ms after stimulus presentation. These results, indicating impaired selective attention by a blockade of dopamine D2 receptors, were further accompanied with increased mismatch negativity (MMN), elicited by involuntary detection of task-irrelevant deviants. Taken together, haloperidol seemed to induce functional changes in neural networks accounting for both selective and involuntary attention, suggesting modulation of these functions by dopamine D2 receptors.
Kähkönen
S
S
BioMag Laboratory, Medical Engineering Centre, Helsinki University Central Hospital, Helsinki, Finland. seppo.kahkonen@helsinki.fi
Ahveninen
J
J
Jääskeläinen
I P
IP
Kaakkola
S
S
Näätänen
R
R
Huttunen
J
J
Pekkonen
E
E
D000161:Acoustic Stimulation; D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001288:Attention / Q000187:drug effects*; D001307:Auditory Perception / Q000187:drug effects; D004311:Double-Blind Method; D004569:Electroencephalography / Q000187:drug effects*; D005260:Female; D007839:Functional Laterality; D006220:Haloperidol / Q000494:pharmacology*; D006801:Humans; D015225:Magnetoencephalography / Q000187:drug effects*; D008297:Male
D014150:Antipsychotic Agents; D006220:Haloperidol